RE: Interesting2 Oct 2025 09:27
Hi Pal
Well described in the RNS
This agreement brings together MIM's innovation and IB's commercialization strength to accelerate access to a powerful, clinically validated imaging solution," said Dr. Yi Wang, PhD, MIM's President. "The fact that QSMetric is both FDA-cleared and patent-protected underscores its scientific rigor and commercial readiness."
The collaboration also opens the door to joint development initiatives, including:
· Integration of QSMetric with IB's solutions to enhance neuro characterization.
· Expansion into multi-parametric imaging workflows for neuro-oncology, neurodegeneration, and vascular disorders.
· Co-development of AI-driven analytics and clinical decision support tools leveraging QSMetric data.
Agree MS enthusiastic about the partnership
Hopefully opens a few doors .
Hopefully too we will news of phase 1 completion and phase 2 future 🤞